Nanoform and Revio Therapeutics Partner to Develop GLIORA, a Novel Hydrogel Nanoformulation for High-Grade Glioma Treatment
核心洞察
Nanoform Finland (搜索) and Revio Therapeutics (搜索) announced a partnership to co-develop GLIORA (搜索), a nano-formulated combination of olaparib and temozolomide delivered as a locally-administered, long-acting hydrogel for high-grade glioma treatment.
GLIORA (搜索) is designed to overcome limitations of current oral temozolomide therapy through localized delivery to the tumor resection bed during surgery, potentially enhancing tumor control and reducing systemic side effects.
The program is expected to enter clinical trials by the second half of 2026, with potential commercial availability by 2029-30, representing a significant advancement in brain tumor treatment approaches.
Nanoform Finland (搜索) Plc announced a strategic partnership with Revio Therapeutics (搜索) to co-develop and commercialize GLIORA (搜索), an innovative nano-formulated combination therapy for high-grade glioma, a fast-growing and aggressive type of brain tumor. The collaboration aims to address significant unmet medical needs in brain cancer treatment through advanced drug delivery technology.
Novel Combination Therapy Approach
GLIORA (搜索) combines olaparib (originally developed by AstraZeneca as Lynparza®) and temozolomide (originally developed by Merck & Company (搜索) as Temodar®) in a locally-administered, long-acting, thermo-responsive hydrogel formulation. The treatment is designed to overcome the limitations of current standard-of-care oral temozolomide through localized delivery directly to the tumor resection bed during surgery.
By incorporating olaparib, a poly (ADP-ribose) polymerase (搜索) (PARP (搜索)) inhibitor that is mechanistically synergistic with temozolomide, the formulation amplifies chemo and radiotherapy-induced DNA damage while suppressing tumor repair pathways. This approach is expected to enhance tumor control during the critical post-surgical window, reduce the likelihood of resistance and recurrence, and minimize systemic exposure and side effects.
Advanced Manufacturing Technology
Under the partnership agreement, Nanoform will utilize its proprietary Controlled Expansion of Supercritical Solutions (CESS®) technology under GMP conditions to nanoform the APIs and intermediates at its Helsinki facility. The company will also employ its proprietary thermo-responsive hydrogel technology to develop the finished product prototype.
"Developing a product like GLIORA (搜索) for local, long-acting and safe delivery into a small dosing volume to fit into the tumor void space requires exquisite control over several parameters such as particle size, morphology, drug loading, release characteristics, and dose-ratio control. This is where Nanoform's proprietary platform technology and capabilities shines through," said Prof. Edward Häggström, CEO of Nanoform.
Clinical Development Timeline
Revio Therapeutics (搜索) will lead the preclinical and clinical development of the program and will be responsible for eventual manufacturing and supply of the final sterile dosage form. Prototype development and testing is currently at an advanced stage, with the program expected to enter clinical trials by the second half of 2026.
Subject to successful co-development and commercialization, GLIORA (搜索) could be commercially available by 2029-30. While olaparib is not currently approved for glioblastoma multiforme (GBM), its oral co-administration with temozolomide has shown promise in clinical settings, despite dose-limiting side effects that the new formulation aims to address.
Partnership Structure and Financial Terms
Development costs and all licensing and commercial revenues will be shared equally between the partners, with Nanoform receiving an additional €1.5 million in accelerated revenue-share payments. This collaborative approach leverages the complementary expertise of both companies in advancing innovative cancer treatments.
Sreevatsa Natarajan, CEO of Revio Therapeutics (搜索), emphasized the potential impact: "We're delighted to collaborate with Nanoform on GLIORA (搜索), which we expect will be a meaningful step forward in how gliomas can be treated. By uniting the proven mechanisms and synergy of temozolomide and olaparib in a long-acting, locally delivered format, GLIORA has the potential to redefine therapeutic outcomes in a disease with profound unmet need."
The partnership represents a significant step forward in addressing the challenges of treating high-grade gliomas, combining proven therapeutic mechanisms with advanced nanotechnology and targeted delivery systems to potentially improve patient outcomes in this difficult-to-treat cancer.